Every movement of the human body, acting as a biological machine\u2014taking a step, speaking, or simply breathing\u2014is based on the continuous operation of the muscles and the nervous system. However, for individuals living with Duchenne Muscular Dystrophy (DMD), performing even daily routine actions is fraught with immense difficulties.<\/p>\n
Fortunately, research into this rare genetic disorder has reached unprecedented scales today. While for most of history, patients with Duchenne had almost no medical alternatives, today, medicine\u2014swept up in the rhythm of progress\u2014allows us to speak not only of halting the disease but even of restoring lost functions.<\/p>\n
Before answering the question of what modern medicine offers to combat this rare disease, let us review its historical and epidemiological landscape.<\/p>\n
The first clinical picture of the disease was described as early as the 1830s by Neapolitan physicians Giovanni Semmola and Gaetano Conte. However, the syndrome was named in honor of the French neurologist Guillaume-Benjamin-Amand Duchenne.<\/p>\n
In a paper published in 1861, the scientist detailed the case of a boy with this severe condition. Interestingly, Duchenne was presumably the first to develop and utilize a technique for taking a muscle biopsy from a living patient for research purposes, thereby pioneering the scientific study of this genetic disorder.<\/p>\n
Regarding epidemiology, Duchenne Muscular Dystrophy belongs to a broad group of neuromuscular diseases. Due to its genetic specifics, the disease occurs almost exclusively in males. Statistically, on average, one in every 3,500 to 5,000 newborn boys is born with DMD.<\/p>\n
Symptoms typically manifest in early childhood. However, it is crucial to emphasize that women carrying the disease gene face certain risks as well. They have a higher-than-average risk of developing cardiomyopathy, which is why regular cardiological monitoring starting from adolescence is vitally important for them.<\/p>\n
Managing Duchenne is not limited to a single specific area. It is a highly complex process requiring the collaborative work of multidisciplinary specialists, including neurologists, cardiologists, pulmonologists, and physical therapists.<\/p>\n
In the past decade, the U.S. Food and Drug Administration (FDA) has approved numerous new targeted therapies, radically changing approaches to combating the disease and providing medicine with real tools to tackle Duchenne.<\/p>\n
The primary and most common line of treatment consists of corticosteroids (e.g., Prednisone, Emflaza, Agamree). These medications effectively slow down muscle weakening. With their help, patients retain the ability to move independently for much longer, which positively impacts their quality of life.<\/p>\n
The new gene therapy, Elevidys, is considered the most revolutionary advancement. Its mechanism of action is quite intriguing. Utilizing a specially modified virus, the drug introduces the dystrophin gene into the cells. As a result, the body begins to produce so-called “micro-dystrophin,” which aims to mitigate the course of the disease and functionally bring it closer to a condition similar to Becker muscular dystrophy.<\/p>\n
Another innovative approach is “Exon Skipping” therapy. The specific medications used in this method (Amondys 45, Viltepso, Exondys 51) essentially force the body to bypass, or skip, the damaged section when reading the genetic code. Consequently, a shorter but partially functional dystrophin protein is created.<\/p>\n
Additionally, promoting tissue regeneration forms a significant part of the treatment. For instance, the drug Duvyzat acts directly at the enzymatic level, sharply reducing muscle inflammation and fibrosis (the development of scar tissue). This approach protects muscle tissue from premature cell death and damage.<\/p>\n
All the medications and therapeutic interventions listed in the text are officially approved by the U.S. Food and Drug Administration (FDA). Furthermore, the European Medicines Agency (EMA) has approved Agamree, a next-generation corticosteroid, and Duvyzat, the latest muscle-tissue-protecting drug.<\/p>\n
While existing methods can significantly slow disease progression and extend patient survival, the progress of medicine, fortunately, cannot be stopped.<\/p>\n
At this stage, the main target of a new wave of research is shifting from disease management to the regeneration of lost muscle tissue. Scientists are actively studying mechanisms to block myostatin (a protein that inhibits muscle growth) and exploring the potential of stem cell therapy.<\/p>\n
In parallel, new biomarkers are being introduced, allowing physicians to assess disease progression and therapeutic efficacy long before physical symptoms manifest.<\/p>\n
To highlight specific research, according to a recent study published in the authoritative scientific journal Stem Cell Reports<\/i>, scientists at the American clinic Cedars-Sinai halted the progression of Duchenne muscular dystrophy in laboratory models using an innovative cell therapy.<\/p>\n
In the experiment, scientists utilized cardiosphere-derived cells (CDCs), which possess a unique regenerative capacity to repair damaged tissues. In laboratory models, this therapy was administered monthly over the course of a year. As a result, these models fully retained muscle strength and physical endurance, whereas the condition of the untreated group deteriorated catastrophically.<\/p>\n
Unfortunately, conventional medications available to date focus solely on slowing disease progression, whereas this new method significantly delayed the onset of muscle weakness at an early stage.<\/p>\n
Moreover, a new cell-based drug derived from these cells, named deramiocel, is currently undergoing advanced clinical trials in humans. The study aims to confirm how effectively the drug combats heart failure and skeletal muscle damage in patients.<\/p>\n
According to the scientists, this is a historic milestone in neuromuscular medicine, which could safeguard individuals with Duchenne syndrome from fatal wasting of the heart and lung muscles in the future.<\/p>\n
It must be emphasized, almost as a fundamental truth, that a diagnosis of Duchenne Muscular Dystrophy today no longer means a short life spent waiting for death\u2014nor does it mean the paralysis of patients and their families by hopelessness.<\/p>\n","protected":false},"excerpt":{"rendered":"
Every movement of the human body, acting as a biological machine\u2014taking a step, speaking, or simply breathing\u2014is based on the continuous operation of the muscles and the nervous system. However, for individuals living with Duchenne Muscular Dystrophy (DMD), performing even daily routine actions is fraught with immense difficulties. Fortunately, research into this rare genetic disorder […]<\/p>\n","protected":false},"author":2,"featured_media":18992,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1594,1665,1587,1657,1659],"tags":[5683],"class_list":["post-18993","post","type-post","status-publish","format-standard","has-post-thumbnail","category-news","category-public-health","category-research","category-science","category-technologies","tag-duchenne"],"acf":[],"_links":{"self":[{"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/posts\/18993","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/comments?post=18993"}],"version-history":[{"count":1,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/posts\/18993\/revisions"}],"predecessor-version":[{"id":18996,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/posts\/18993\/revisions\/18996"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/media\/18992"}],"wp:attachment":[{"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/media?parent=18993"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/categories?post=18993"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/tags?post=18993"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}